Tomography News and Research

RSS

ThromboGenics completes enrollment in second microplasmin Phase III trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

16 Dec 2009

Cerebrospinal fluid signature and PiB imaging help predict Alzheimer's disease

Early Alzheimer's disease detected by a compound that binds to brain plaques appears likely to progress into symptomatic Alzheimer's disease with dementia, according to a report in the December issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Dec 2009

Risks and benefits of CT scans

Doses of radiation from commonly performed computed tomography (CT) scans vary widely, appear higher than generally believed and may contribute to an estimated tens of thousands of future cancer cases, according to two reports in the December 14/28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Dec 2009

FDA publishes cGMPs for PET drugs

The U.S. Food and Drug Administration (FDA) announced publication of a final regulation on current good manufacturing practices (cGMPs) for the production of positron emission tomography (PET) drugs, as well as a guidance document describing acceptable approaches that would enable PET drug producers to meet the requirements in the proposed regulation.

15 Dec 2009

Brain plaques associated with increased risk of Alzheimer's disease

Scientists have long assumed that amyloid brain plaques found in autopsies of Alzheimer's patients are harmful and cause Alzheimer's disease. But autopsies of people with no signs of mental impairment have also revealed brain plaques, challenging this theory.

15 Dec 2009

CONNECT announces the winners of MIP Awards

CONNECT, one of the nation's most successful regional economic development programs for high technology and life science innovators, today announced the winners of the 22nd Annual Most Innovative New Product (MIP) Awards.

11 Dec 2009

ThromboGenics initiates Phase II trial of microplasmin for wet AMD

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD).

11 Dec 2009

Most antidepressant medications raise serotonin levels and miss key target of clinical depression

A key brain protein called monoamine oxidase A (MAO-A) - is highly elevated during clinical depression yet is unaffected by treatment with commonly used antidepressants, according to an important study published today in the Archives of General Psychiatry. The study has important implications for our understanding of why antidepressants don't always work.

9 Dec 2009

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

8 Dec 2009

Excess radiation exposure during CT perfusion imaging: FDA issues interim recommendations

As part of an ongoing investigation into cases of excess radiation during CT perfusion imaging of the brain, the U.S. Food and Drug Administration today provided imaging facilities and practitioners with interim recommendations to help prevent additional problems.

8 Dec 2009

H1N1 virus produces pulmonary damage similar to earlier flu pandemics

In fatal cases of 2009 H1N1 influenza, the virus can damage cells throughout the respiratory airway, much like the viruses that caused the 1918 and 1957 influenza pandemics, report researchers from the National Institutes of Health (NIH) and the New York City Office of Chief Medical Examiner.

8 Dec 2009

New diagnostic guidelines for inexpensive and accurate detection of lung cancer

A simple, inexpensive computer tool that measures volume changes in the size of suspicious nodules in the lungs picked up by a CT scanner can rule out non-cancerous ones with almost perfect accuracy and enable doctors to diagnose true cancers with fewer, less expensive and less invasive tests.

5 Dec 2009

Stentys commences enrollment in its comparative stent study

Medical device pioneer Stentys announced today that the first patient has been enrolled into the ‘APPOSITION II’ clinical study—a randomized trial comparing the Stentys self-expanding stent with a conventional balloon-expandable stent in AMI patients. The primary endpoint of the ‘APPOSITION II’ study is stent strut apposition at day three post-procedure via extremely high-resolution OCT (optical coherence tomography) imaging.

4 Dec 2009

Cancer-free status does not lead to resumption of smoking among former smokers

Assurance of a cancer-free status did not prompt people participating in a long-term computerized tomography (CT) lung-cancer screening program to pick up their cigarettes again, researchers wrote in a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

4 Dec 2009

Caliper Life Sciences releases Living Image 4.0 software for its IVIS in vivo imaging systems

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 software for IVIS® in vivo imaging systems. Living Image software drives the more than 800 Caliper IVIS systems currently installed in laboratories worldwide.

3 Dec 2009

TGen scientists win $1,000 prize for best scientific paper presented at BIBM09

A team of scientists at the Translational Genomics Research Institute (TGen) won a $1,000 prize for best scientific paper presented at BIBM09, a premier bioinformatics and biomedicine conference.

3 Dec 2009

CT imaging after chemotherapy with bevacizumab may help predict overall survival

Preliminary research suggests that criteria based on computed tomography (CT) imaging of changes in tumors from colorectal liver metastases after chemotherapy with the drug bevacizumab may have the potential to predict overall survival, according to a study in the December 2 issue of JAMA.

3 Dec 2009

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

Using routine computed tomography (CT) imaging to analyze form and structural changes to colorectal liver metastasis after bevacizumab and chemotherapy may predict overall survival, according to research from The University of Texas M. D. Anderson Cancer Center.

2 Dec 2009

Pulmonary embolism can be diagnosed by combining SPECT and low-dose CT, shows research

When it comes to diagnosing pulmonary embolism-a sudden blockage in the lung artery that could be deadly if not treated-which technique is the most effective?

2 Dec 2009

Clinical trail shows PAD patients also experience asymptomatic heart disease

Results of a randomized, controlled clinical trial presented today at the annual meeting of the Radiological Society of North America (RSNA) reveal that one in five patients with narrowing or blockage in arteries that supply blood to the legs and other parts of the body also have significant but silent coronary artery disease.

1 Dec 2009